• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Sean Paul Little

    3/19/21 7:00:19 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care
    Get the next $NVUS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Little Paul Sean

    (Last) (First) (Middle)
    C/O ELEDON PHARMACEUTICALS, INC.
    19900 MACARTHUR BLVD., SUITE 550

    (Street)
    IRVINE CA 92612

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/15/2021
    3. Issuer Name and Ticker or Trading Symbol
    Eledon Pharmaceuticals, Inc. [ ELDN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 03/15/2031 Common Stock 160,000 13.94 D
    Explanation of Responses:
    1. This option represents a right to purchase up to 160,000 shares of Common Stock, which option vests with respect to 40,000 shares on March 15, 2022, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending March 15, 2025.
    Remarks:
    Ex. 24 - Power of Attorney No securities are beneficially owned.
    /s/ Ryan A. Murr, as attorney-in-fact for Paul Little 03/19/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

    Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody IRVINE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond. 2020 a

    1/4/21 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    Novus Therapeutics Announces Results of Special Meeting of Stockholders

    IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced results from a special meeting of stockholders that was held on Friday, December 19, 2020. During the meeting, Novus’ stockholders approved a proposal for the issuance of common shares upon conversion of Series X¹ non-voting convertible preferred stock issued at the time of the company’s acquisition of Anelixis Therapeutics, Inc., and concurrent private placement (PI

    12/22/20 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors. “We are delighted to welcome June to our board of directors as Novus continues on this next phase of its evolution,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Novus Therapeutics, Inc. “Over a twenty plus year career as a clinician, academic, executive, and respected leader in the biote

    12/9/20 8:30:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    SEC Filings

    View All

    SEC Form 8-K filed by Novus Therapeutics, Inc.

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    3/15/21 2:00:32 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K filed

    8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

    1/7/21 8:00:54 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    1/5/21 4:38:07 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 4:35:45 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 4:17:16 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

    2/16/21 3:14:46 PM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Leadership Updates

    Live Leadership Updates

    View All

    Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors. “We are delighted to welcome June to our board of directors as Novus continues on this next phase of its evolution,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Novus Therapeutics, Inc. “Over a twenty plus year career as a clinician, academic, executive, and respected leader in the biote

    12/9/20 8:30:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Financials

    Live finance-specific insights

    View All

    Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

    Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody IRVINE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond. 2020 a

    1/4/21 8:00:00 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care

    $NVUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Sean Paul Little

    3 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

    3/19/21 7:00:19 AM ET
    $NVUS
    Major Pharmaceuticals
    Health Care